Latest News

JPMorgan’s big healthcare conference goes virtual on Omicron concerns

December 15, 2021 | The Wall Street Journal

JPMorgan Chase & Co. is moving its big annual healthcare conference in San Francisco to a virtual setting, telling participants the spreading Omicron variant of Covid-19 had made the in-person gathering too risky. The bank’s annual gathering is one of the biggest events for global healthcare professionals and CEOs, and it is often full of deal making. This year’s event, scheduled for the middle of January, will be the 40th version. The move comes after several biotechnology companies pulled out of planned in-person appearances, which were first reported on Tuesday by Stat News.

Back to top

Pitchbook US VC Valuations Report Shows Record Exit Trends

August 20, 2021 | Pitchbook

Record levels of dry powder and a fierce influx of nontraditional investors into the venture ecosystem have buoyed VC-backed company valuations to record heights in the second quarter of this year. PitchBook’s latest US VC Valuations Report examines how startup valuations across the venture lifecycle and sectors have changed in 2021. Among the report's findings is an observation that exit valuations grew at a decade-record rate, with median acquisition and public listings step-ups of 2.2x and 1.7x, respectively, from their last private market values.

Back to top

Health care’s innovation shifts into high gear

April 21, 2021 | Janus Henderson Investors

For much of the past year, efforts by biopharma companies to rein in the COVID-19 pandemic have dominated the news coming out of the health care sector. The industry’s response – developing vaccines and treatments for the novel coronavirus in less than a year – is one for the record books. But as the end of the pandemic comes into sight, we believe health care’s achievements are only getting started. Last year, the U.S. Food and Drug Administration (FDA) approved 52 novel drugs, excluding medicines for COVID-19. That sum is not far from the 2018 record of 59 and occurred despite lockdown measures that closed labs and slowed drug-manufacturing site inspections At the same time, some of the first COVID-19 vaccines to be granted emergency use authorization were based on advance drug modalities that previously had never moved beyond the research lab.

Back to top

Leading life science investment advisor Torreya shares high level of sector optimism for 2021.

January 11, 2021 | Torreya

Torreya, a leading global investment banking boutique providing mergers and acquisitions, capital markets, and licensing advisory services to life sciences companies, today released a report sharing broad optimism for the pharmaceutical sector in 2021. They analyze recent market and political factors to predict strong markets for drug sales, private investment, and vertical M&A activities.

Back to top